#United States #San Rafael #BioMarin #VOXZOGO #Hypochondroplasia

BioMarin's Phase 3 Study Confirms Efficacy of VOXZOGO in Hypochondroplasia Children

On May 20, 2026, BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) shared noteworthy findings from their Phase 3 CANOPY-HCH-3 study concerning VOXZOGO® (vosoritide), a treatment designed for children diagnosed with hypochondroplasia. This pivotal study successfully met its primary endpoint, demonstrating a notable enhancement in annualized growth velocity (AGV) after 52 weeks of treatment.

The trial's results illustrated an average increase of 2.33 cm/year in AGV for children receiving VOXZOGO compared to those in the placebo group, with a statistically significant p-value of less than 0.0001. Additionally, the study highlighted significant improvements in both standing height and height Z-score, all against the placebo group, marking a groundbreaking achievement for this rare genetic condition.

Moreover, the trial reported a significant increase in arm span measurements at week 52—a secondary endpoint critical for assessing functional independence in children. Such improvements are essential, as they are expected to enhance daily activities and overall independence for those living with hypochondroplasia, ultimately impacting their quality of life positively.

Expert Opinions on the Breakthrough

Dr. Andrew Dauber, the lead study investigator and Chief of Endocrinology at Children's National Hospital, expressed excitement over these results, emphasizing how they represent a potential milestone after years of limited treatment options. He remarked, _"Seeing these improvements in growth is a milestone we have hoped for, offering a new era in care for children with hypochondroplasia."_

In parallel, Greg Friberg, M.D., BioMarin's Executive Vice President and Chief Research Development Officer, conveyed his enthusiasm, recognizing VOXZOGO as a potential game-changer in the treatment landscape of this condition. He noted, _“These results exceeded our expectations and demonstrate the promise VOXZOGO has in fundamentally changing how we approach hypochondroplasia.”_

Safety Profile Consistency

The safety findings from this study corresponded with the established safety profile noted in previous studies of VOXZOGO for achondroplasia, and no new safety concerns were identified. As such, BioMarin is preparing to submit a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA), with plans for submissions to the European Medicines Agency (EMA) and other global health regulatory bodies in the near future.

Understanding Hypochondroplasia

Hypochondroplasia is a rare genetic skeletal disorder that hampers bone growth, resulting in disproportionate short stature and unique skeletal characteristics. The disorder can impact various aspects of physical functionality and overall quality of life. Currently, there are no approved treatments in the U.S. or Europe specifically addressing hypochondroplasia.

VOXZOGO is already established in the U.S., Japan, and Australia for promoting linear growth in children with achondroplasia—with ongoing efforts to broaden its approval for hypochondroplasia.

Individuals interested in further details regarding clinical trials related to hypochondroplasia and other conditions may refer to BioMarin's clinical trials portal.

This significant advancement in VOXZOGO's effectiveness opens the door to better management of hypochondroplasia, an encouraging development for families impacted by the condition. The upcoming presentations at medical conferences will provide further insights into this promising therapy, shedding light on its transformative potential for improving the lives of affected children worldwide.

Conclusion

As BioMarin continues to unravel the full potential of VOXZOGO, the hope remains for children diagnosed with hypochondroplasia to gain access to a treatment that could significantly improve their growth and overall life experiences.